Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Alzheimer's Research & Therapy
Published in: Alzheimer's Research & Therapy 1/2023

Open Access 01-12-2023 | Alzheimer's Disease | Research

A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease

Authors: Ove Almkvist, Agneta Nordberg

Published in: Alzheimer's Research & Therapy | Issue 1/2023

Login to get access

Abstract

Background

It is possible to calculate the number of years to the expected clinical onset (YECO) of autosomal-dominant Alzheimer’s disease (adAD). A similar time scale is lacking for sporadic Alzheimer’s disease (sAD). The purpose was to design and validate a time scale in YECO for patients with sAD in relation to CSF and PET biomarkers.

Methods

Patients diagnosed with Alzheimer’s disease (AD, n = 48) or mild cognitive impairment (MCI, n = 46) participated in the study. They underwent a standardized clinical examination at the Memory clinic, Karolinska University Hospital, Stockholm, Sweden, which included present and previous medical history, laboratory screening, cognitive assessment, CSF biomarkers (Aβ42, total-tau, and p-tau), and an MRI of the brain. They were also assessed with two PET tracers, 11C-Pittsburgh compound B and 18F-fluorodeoxyglucose. Assuming concordance of cognitive decline in sAD and adAD, YECO for these patients was calculated using equations for the relationship between cognitive performance, YECO, and years of education in adAD (Almkvist et al. J Int Neuropsychol Soc 23:195-203, 2017).

Results

The mean current point of disease progression was 3.2 years after the estimated clinical onset in patients with sAD and 3.4 years prior to the estimated clinical onset in patients with MCI, as indicated by the median YECO from five cognitive tests. The associations between YECO and biomarkers were significant, while those between chronological age and biomarkers were nonsignificant. The estimated disease onset (chronological age minus YECO) followed a bimodal distribution with frequency maxima before (early-onset) and after (late-onset) 65 years of age. The early- and late-onset subgroups differed significantly in biomarkers and cognition, but after control for YECO, this difference disappeared for all except the APOE e4 gene (more frequent in early- than in late-onset).

Conclusions

A novel time scale in years of disease progression based on cognition was designed and validated in patients with AD using CSF and PET biomarkers. Two early- and late-disease onset subgroups were identified differing with respect to APOE e4.
Appendix
Available only for authorised users
Literature
1.
2.
Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis. 2010;19:1401–8.PubMedCrossRef
3.
Mendez MF. Early-onset Alzheimer Disease and Its Variants. Continuum (Minneap Minn). 2019;2:34–51.
4.
5.
6.
Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, et al. Familial and sporadic Alzheimer’s disease: neuropathology cannot exclude a final common pathway. Neurology. 1996;46:406–12.PubMedCrossRef
7.
Ringman JM, Monsell S, Ng DW, Zhou Y, Nguyen A, Coppola G, et al. Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol. 2016;75:284–90.PubMedPubMedCentralCrossRef
8.
Thaker U, McDonagh AM, Iwatsubo T, Lendon CL, Pickering-Brown SM, Mann DM. Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer’s disease. Neuropathol Appl Neurobiol. 2003;29:35–44.PubMedCrossRef
9.
Buckles VD, Xiong C, Bateman RJ, Hassenstab J, Allegri R, Berman SB, et al; Dominantly Inherited Alzheimer's Network. Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. Alzheimers Dement. 2012; https://​doi.​org/​10.​1002/​alz.​12505.
10.
Day GS, Musiek ES, Roe CM, Norton J, Goate AM, Cruchaga C, et al. Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA Neurol. 2016;73:1125–32.PubMedPubMedCentralCrossRef
11.
Eckerström C, Klasson N, Olsson E, Selnes P, Rolstad S, Wallin A. Similar pattern of atrophy in early- and late-onset Alzheimer’s disease. Alzheimers Dement (Amst). 2018;10:253–9.PubMedCrossRef
12.
Tentolouris-Piperas V, Ryan NS, Thomas DL, Kinnunen KM. Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer’s disease. Brain Res. 2017;1655:23–32.PubMedCrossRef
13.
Thomas JB, Brier MR, Bateman RJ, Snyder AZ, Benzinger TL, Xiong C, et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol. 2014;71:1111–22.PubMedPubMedCentralCrossRef
14.
Lista S, O’Bryant SE, Blennow K, Dubois B, Hugon J, Zetterberg H, et al. Biomarkers in Sporadic and Familial Alzheimer’s Disease. Disease J Alzheimers Dis. 2015;47:291–317.PubMedCrossRef
15.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984;34:939–44.PubMedCrossRef
16.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-V). Washington, DC: American Psychiatric Association; 2013.CrossRef
17.
The ICD-10 classification of mental and behavioural disorders: clinical descriptors and diagnostic guidelines. World Health Organization; 1992.
18.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92.PubMedPubMedCentralCrossRef
19.
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29.PubMedCrossRef
20.
Almkvist O, Rodriguez-Vieitez E, Thordardottir S, Amberla K, Axelman K, Basun H, et al. Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer’s Disease. J Int Neuropsychol Soc. 2017;23:195–203.PubMedCrossRef
21.
Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Dominantly Inherited Alzheimer Network. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253–60.PubMedPubMedCentralCrossRef
22.
Aguirre-Acevedo DC, Lopera F, Henao E, Tirado V, Munoz C, Giraldo M, et al. Cognitive decline in a Colombian kindred with autosomal-dominant Alzheimer Disease: A retrospective cohort study. JAMA Neurol. 2016;73:431–8.PubMedPubMedCentralCrossRef
23.
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795–804.
24.
Storand M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and psychological characteristics of the initial cohort of the dominantly inherited Alzheimer network (DIAN). Neuropsychology. 2014;28:19–29.CrossRef
25.
Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, et al.; Dominantly Inherited Alzheimer Network. Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology. 2015;85:790–798.
26.
Yau WY, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, et al. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer’s disease: A prospective cohort study. Lancet Neurol. 2015;14:804–13.PubMedPubMedCentralCrossRef
27.
Bilgel M, Jedynak BM. for the Alzheimer’s Neruroimaging Initiative Predicting time to dementia using a quantitative tmplate of disease progression. Alzheimers Dement (Amst). 2019;11:205–15.PubMedCrossRef
28.
Ottoy J, Niemantsverdriet E, Verhaeghe J, De Roeck E, Struyfs H, Somers C, et al. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. Neuroimage Clin. 2019;22: 101771.PubMedPubMedCentralCrossRef
29.
Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, et al. Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer’s disease. Brain. 2018;141:1186–200.PubMedPubMedCentralCrossRef
30.
Hadjichrysanthou C, Evans S, Bajaj S, Siakallis LC, McRae-McKee K, et al.; Alzheimer’s Disease Neuroimaging Initiative. The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. Alzheimers Res Ther. 2020;12:74.
31.
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. Contributors NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.PubMedPubMedCentralCrossRef
32.
Brück CC, Wolters FJ, Ikram MA, de Kok IMCM. Heterogeneity in Reports of Dementia Disease Duration and Severity: A Review of the Literature. J Alzheimers Dis. 2021;84:1515–22.PubMedPubMedCentralCrossRef
33.
Jylhävä J, Pedersen NL, Hägg S. Biological Age Predictors. EBioMedicine. 2017;29–36.
34.
Blennow K, Zetterberg H. Fluid biomarker-based molecular phenotyping of Alzheimer’s disease patients in research and clinical settings. Prog Mol Biol Transl Sci. 2019;168:3–23.PubMedCrossRef
35.
Lesman-Segev OH, La Joie R, Iaccarino L, Lobach I, Rosen HJ, Seo SW, et al. Diagnostic Accuracy of Amyloid versus 18 F-Fluorodeoxyglucose Positron Emission Tomography in Autopsy-Confirmed Dementia. Ann Neurol. 2020;89:389–401.PubMedPubMedCentralCrossRef
36.
Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer’s Disease. J Alzheimers Dis. 2015;45:1077–88.PubMedCrossRef
37.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR), 4th ed, text revision. Washington, DC:American Psychiatric Association, 2000.
38.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment: Beyond controversies, towards a consensus. J Int Med. 2004;256:240–6.CrossRef
39.
Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol. 2020;19:951–62.PubMedCrossRef
40.
Bartfai A, Nyman, H, Stegman B. Wechsler Adult Intelligence Scale revised: WAIS-R Manual. Psykologiförlaget, Stockholm, Sweden.
41.
Wechsler D. Wechsler Adult Intelligence Scale revised: WAIS-R Manual. New York: Psychological Corporation; 1981.
42.
Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. New York: Oxford University Press; 2004.
43.
Bergman I, Almkvist O. The effect of age on fluid intelligence is fully mediated by physical health. Arch Gerontol Geriatr. 2014;57:100–9.CrossRef
44.
Almkvist O, Rodriguez-Vieitez E, Thordardottir S, Nordberg A, Viitanen M, Lannfelt L, et al. Longitudinal cognitive decline in autosomal-dominant Alzheimer’s disease varies with mutations in APP and PSEN1 genes. Neurobiol Aging. 2019;82:40–7.PubMedCrossRef
45.
Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ. Amyloid Biomarker Study Group (2022) Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurol. 2022;79:228–43.PubMedCrossRef
46.
Marra C, Bizzarro A, Daniele A, De Luca l, Ferraccioli M, Valenza A, et al. Apolipoprotein E ε4 allele differentially affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer’s Disease patients. Dement Geriatr Cogn Disord. 2004;18:125–131.
47.
Wattmo C, Wallin ÅK. Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years. Alzheimers Res Ther. 2017;31:70.CrossRef
48.
Elahi FM, Casaletto KB, La Joie R, Walters SM, Harvey D, Wolf A, et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer’s disease. Alzheimers Dement. 2020;16:681–95.PubMedPubMedCentralCrossRef
49.
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3.PubMedCrossRef
50.
Tellechea P, Pujol N, Esteve-Bellocha P, Echevestea B, García-Eulate MR, Arbizuc J, et al. Early and late-onset Alzheimer disease: Are they the same entity? Neurologia (Engl Ed). 2018;33:244–53.PubMedCrossRef
51.
Barnes J, Dickerson BC, Frost C, Jiskoot LC, Wolk D, van der Flier WM. Alzheimer’s disease first symptoms are age dependent: Evidence from the NACC dataset. Alzheimers Dement. 2015;11:1349–57.PubMedPubMedCentralCrossRef
52.
Qiu Y, Jacobs DM, Messer K, Salmon DP, Feldman HH. Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic features. Neurology. 2016;93:e778–90.CrossRef
53.
Crane PK, Trittschuh E, Mukherjee S, Saykin AJ, Sanders RE, Larson EB, et al.; Executive Prominent Alzheimer's Disease: Genetics and Risk Factors (EPAD:GRF) Investigators. Incidence of cognitively defined late-onset Alzheimer's dementia subgroups from a prospective cohort study. Alzheimers Dement. 2017;13:1307–1316.
54.
55.
Peter J, Abdulkadir A, Kaller C, Kümmerer D, Hüll M, Vach W, et al. Subgroups of Alzheimer’s disease: stability of empirical clusters over time. J Alzheimers Dis. 2014;42:651–61.PubMedCrossRef
56.
Scheltens NM, Galindo-Garre F, Pijnenburg YA, van der Vlies AE, Smits LL, Koene T, et al. The identification of cognitive subtypes in Alzheimer’s disease dementia using latent class analysis. J Neurol Neurosurg Psychiatr. 2016;87:235–43.CrossRef
57.
Stopford CL, Snowden JS, Thompson JC, Neary D. Distinct memory profiles in Alzheimer’s disease. Cortex. 2007;43:846–57.PubMedCrossRef
58.
Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785–96.PubMedPubMedCentralCrossRef
59.
Whitwell JL, Dickson DW, Murray ME, Weigand SD, Tosakulwong N, Senjem ML, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: a case-control study. Lancet Neurol. 2012;11:868–77.PubMedPubMedCentralCrossRef
Metadata
Title
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease
Authors
Ove Almkvist
Agneta Nordberg
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 1/2023
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-023-01231-8

Other articles of this Issue 1/2023

Alzheimer's Research & Therapy 1/2023 Go to the issue

Research

In vivo cortical diffusion imaging relates to Alzheimer’s disease neuropathology

Research

Early visual alterations in individuals at-risk of Alzheimer’s disease: a multidisciplinary approach

Research

Frailty in randomised controlled trials for dementia or mild cognitive impairment measured via the frailty index: prevalence and prediction of serious adverse events and attrition

Research

Higher performance for women than men in MRI-based Alzheimer’s disease detection

Research

Subject classification and cross-time prediction based on functional connectivity and white matter microstructure features in a rat model of Alzheimer’s using machine learning

Comment

Blood biomarkers and neurodegeneration in individuals exposed to repetitive head impacts